Profile

HDAX Therapeutics, a biotechnology company pioneering a novel approach to target HDAC6 to address critical unmet medical needs in cardiometabolic/renal and select neurological diseases. Their innovative 2-site binding mechanism has the potential to deliver best-in-class HDAC6-targeting therapeutics and tackles major limitations of first generation compounds. HDAX closed an oversubscribed $4M seed financing round in Q4 2024 to nominate a development candidate and advance its pipeline programs.

HDAX Therapeutics logo
hdaxtx.com

Contact

Event details

Date: June 16 - 19, 2025

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

23 in total
  • 20/20 OptimEyes Technologies Inc.
    20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for…
  • BIOScript/ACCELERA
    Since 2001, BioScript Solutions has supported patients with chronic illnesses and rare diseases by providing…
  • Custom Biologics
    Custom Biologics provides regulatory compliant potency testing and assay services for all phases of…
  • Dalriada Drug Discovery
    Dalriada is a leading North American discovery company pioneering its novel Turn-Key™ model in small molecule…
  • HDAX Therapeutics
    HDAX Therapeutics, a biotechnology company pioneering a novel approach to target HDAC6 to address…
  • ImmunoBiochem Corporation
    ImmunoBiochem is an innovative biopharmaceutical company developing novel bioconjugate therapeutics, such …
  • Invest Ontario
    Invest Ontario is a provincial agency dedicated to securing private sector strategic business and capital…
  • Lumerate
    Raising capital is a key challenge for executives at early-stage therapeutics companies. Lumerate is launching…
  • mDETECT
    mDETECT offers highly sensitive and cost-effective blood tests that can measure tumour behaviour irrespective of…
  • Noa Therapeutics
    Noa Therapeutics is a preclinical biotech company pioneering the development of homeostatic modulating small…
  • Nucro-Technics
    Nucro-Technics is a full-service Contract Support Organization that specializes in the conduct of both GLP…
  • Paradox Immunotherapeutics
    Paradox Immunotherapeutics is a biotech addressing the global burden of protein misfolding diseases—devastating…
  • ProteinQure Inc.
    ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. Its lead…
  • QReserve
    QReserve provides powerful enterprise-grade scheduling and resource management software to world-class…
  • Specific Biologics Inc.
    Specific Biologics is developing Dualase®, an industry-leading genome editing platform with best-in-class…
  • Spiderwort Biotechnologies
    Spiderwort is a platform biomaterials company developing a suite of cellulose-based scaffolds for use in a number…
  • Stiris Research Inc.
    Stiris is a clinical trial management company conducting Phase I-IIIB trials for biotech and…
  • Sussex Research Laboratories Inc.
    Sussex Research Laboratories Inc. (Ottawa, Canada) is recognized as a leader in the design and synthesis of…
  • SYNG Pharma
    SYNG Pharma is developing a new first-in-class diagnostic test and non-hormonal therapy for endometriosis. The…
  • Transpharmation
    Transpharmation is a contract research organisation led by scientists. Recognised by drug developers worldwide…
  • VeriLuce Therapeutics Inc.
    VeriLuce Therapeutics is an early-stage drug company developing novel small molecules targeting in dual…
  • Virano Therapeutics
    Virano is a genetic immunomodulation company, developing next-generation combination products which reprogram the…
  • YYZ Pharmatech Inc.
    YYZ Pharmatech Inc. (“YYZ”) is a deep tech company endeavoring to profoundly progress…